Literature DB >> 33586998

Detection and staging of radio-recurrent prostate cancer using multiparametric MRI.

Jie-Ying Kowa1, Neil Soneji1, S Aslam Sohaib1, Erik Mayer2,3, Stephen Hazell4, Nicholas Butterfield1, Joshua Shur1, Derfel Ap Dafydd1.   

Abstract

OBJECTIVE: We determined the sensitivity and specificity of multiparametric magnetic resonance imaging (MP-MRI) in detection of locally recurrent prostate cancer and extra prostatic extension in the post-radical radiotherapy setting. Histopathological reference standard was whole-mount prostatectomy specimens. We also assessed for any added value of the dynamic contrast enhancement (DCE) sequence in detection and staging of local recurrence.
METHODS: This was a single centre retrospective study. Participants were selected from a database of males treated with salvage prostatectomy for locally recurrent prostate cancer following radiotherapy. All underwent pre-operative prostate-specific antigen assay, positron emission tomography CT, MP-MRI and transperineal template prostate mapping biopsy prior to salvage prostatectomy. MP-MRI performance was assessed using both Prostate Imaging-Reporting and Data System v. 2 and a modified scoring system for the post-treatment setting.
RESULTS: 24 patients were enrolled. Using Prostate Imaging-Reporting and Data System v. 2, sensitivity, specificity, positive predictive value and negative predictive value was 64%, 94%, 98% and 36%. MP-MRI under staged recurrent cancer in 63%. A modified scoring system in which DCE was used as a co-dominant sequence resulted in improved diagnostic sensitivity (61%-76%) following subgroup analysis.
CONCLUSION: Our results show MP-MRI has moderate sensitivity (64%) and high specificity (94%) in detecting radio-recurrent intraprostatic disease, though disease tends to be under quantified and under staged. Greater emphasis on dynamic contrast images in overall scoring can improve diagnostic sensitivity. ADVANCES IN KNOWLEDGE: MP-MRI tends to under quantify and under stage radio-recurrent prostate cancer. DCE has a potentially augmented role in detecting recurrent tumour compared with the de novo setting. This has relevance in the event of any future modified MP-MRI scoring system for the irradiated gland.

Entities:  

Mesh:

Year:  2021        PMID: 33586998      PMCID: PMC8010529          DOI: 10.1259/bjr.20201423

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  33 in total

1.  The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings.

Authors:  Taylan Kara; Deniz Akata; Fadıl Akyol; Muşturay Karçaaltıncaba; Mustafa Özmen
Journal:  Diagn Interv Radiol       Date:  2010-08-12       Impact factor: 2.630

2.  Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI.

Authors:  Chan Kyo Kim; Byung Kwan Park; Hyun Moo Lee
Journal:  J Magn Reson Imaging       Date:  2009-02       Impact factor: 4.813

3.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

4.  Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience.

Authors:  Anna Luzurier; Paul-Hugo Jouve De Guibert; Alexandre Allera; Sarah F Feldman; Pierre Conort; Jean Marc Simon; Pierre Mozer; Eva Compérat; Franck Boudghene; Vincent Servois; Olivier Lucidarme; Benjamin Granger; Raphaele Renard-Penna
Journal:  J Magn Reson Imaging       Date:  2018-03-08       Impact factor: 4.813

5.  Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Authors:  Olivio F Donati; Sung Il Jung; Hebert Alberto Vargas; David H Gultekin; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Michael J Zelefsky; Oguz Akin
Journal:  Radiology       Date:  2013-03-12       Impact factor: 11.105

Review 6.  The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?

Authors:  R Schiavina; F Ceci; M Borghesi; E Brunocilla; V Vagnoni; M Gacci; P Castellucci; C Nanni; G Martorana; S Fanti
Journal:  Curr Radiopharm       Date:  2013-06-06

7.  Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings.

Authors:  Olivier Rouvière; Olivier Valette; Stéphanie Grivolat; Catherine Colin-Pangaud; Raymonde Bouvier; Jean Yves Chapelon; Albert Gelet; Denis Lyonnet
Journal:  Urology       Date:  2004-05       Impact factor: 2.649

8.  Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.

Authors:  Andrei S Purysko; Leonardo K Bittencourt; Jennifer A Bullen; Thomaz R Mostardeiro; Brian R Herts; Eric A Klein
Journal:  AJR Am J Roentgenol       Date:  2017-06-01       Impact factor: 3.959

9.  PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.

Authors:  A El-Shater Bosaily; C Parker; L C Brown; R Gabe; R G Hindley; R Kaplan; M Emberton; H U Ahmed
Journal:  Contemp Clin Trials       Date:  2015-03-03       Impact factor: 2.226

10.  Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy.

Authors:  Catarina Dinis Fernandes; Ghazaleh Ghobadi; Henk G van der Poel; Jeroen de Jong; Stijn W T P J Heijmink; Ivo Schoots; Iris Walraven; Petra J van Houdt; Milena Smolic; Floris J Pos; Uulke A van der Heide
Journal:  Eur Radiol       Date:  2018-11-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.